Live Breaking News & Updates on Gary Charles Robb

Stay updated with breaking news from Gary charles robb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Corcept Therapeutics (NASDAQ:CORT) Sets New 1-Year High at $34.39

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $34.39 and last traded at $34.20, with a volume of 520210 shares trading hands. The stock had previously closed at $32.87. Wall Street Analyst Weigh In A number of […] ....

United States , Gary Charles Robb , Sean Maduck , Securities Exchange Commission , Burney Co , Corcept Therapeutics Incorporated , Cetera Advisors , Jacobs Levy Equity Management Inc , Hancock Whitney Corp , Janus Henderson Group , Get Free Report , Corcept Therapeutics , Exchange Commission , Whitney Corp , Levy Equity Management , Henderson Group , Therapeutics Incorporated , Corcept Therapeutics Daily ,

Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Gary Charles Robb Sells 11,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Gary Charles Robb Sells 11,000 Shares of Stock
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United States , Gary Charles Robb , Jacobs Levy Equity Management Inc , Clearbridge Investments , Corcept Therapeutics Incorporated , Jupiter Asset Management Ltd , Norden Group , Norges Bank , Get Free Report , Corcept Therapeutics , Therapeutics Incorporated , Levy Equity Management , Asset Management , Corcept Therapeutics Daily ,

Corcept Therapeutics (NASDAQ:CORT) Posts Earnings Results, Beats Expectations By $0.03 EPS

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03, Briefing.com reports. The firm had revenue of $135.41 million for the quarter, compared to analysts’ expectations of $129.27 million. Corcept Therapeutics […] ....

United States , Gary Charles Robb , Danieln Swisher Jr , Dimensional Fund Advisors , Corcept Therapeutics Company Profile , Blackrock Inc , Canaccord Genuity Group , Corcept Therapeutics Incorporated , Vanguard Group Inc , Hermes Inc , Securities Exchange Commission , Corcept Therapeutics , Get Free Report , Therapeutics Trading Down , Director Daniel , Exchange Commission , Street Corp , Fund Advisors , Genuity Group , Therapeutics Incorporated , Corcept Therapeutics Daily , Nasdaq Cort ,